TREACE MEDICAL CONCEPTS INC
TMCINASDAQTrading Snapshot
- Day Range
- $4.54 β $4.68
- 52-Week Range
- $1.17 β $7.08
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 64.9M
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $213M
- Last Q Revenue
- $45M
- P/E Ratio
- -4.8
- P/S Ratio
- 1.4x
- EPS (TTM)
- $-0.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.4%
Why Investors Own TMCI
- βHigh-growth profile β revenue up +22.1% YoY with expanding US Equity exposure.
- βHealthy economics β 30% gross margin and 26% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TREACE MEDICAL CONCEPTS INC
TMCIAbout TREACE MEDICAL CONCEPTS INC
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
TREACE MEDICAL CONCEPTS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TMCI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
TREACE MEDICAL CONCEPTS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.